| Abstract | Penile cancer is a rare tumor in Europe with an incidence of 0.1-0.9 per 100,000 men per year. The success of our therapy is mainly influenced by the presence of lymph node metastases. At first diagnosis 17-45% of patients already harbor lymph node metastases. Bilateral inguinal and pelvic lymphadenectomy is a curative measure in these patients. In cases of gross inguinal metastases neoadjuvant chemotherapy leads to a remission rate of 21-60% and improves the resectability. The influence on survival is not proven. The same holds true for adjuvant therapy following lymphadenectomy.Polychemotherapy rarely leads to long-lasting complete remission in patients with distant metastases. The protocols consist usually of cisplatin, bleomycin, methotrexate, and 5-fluorouracil. The overall remission rate is around 15-32%. Because of the low efficacy of the present chemotherapy regimens, one should follow new strategies, comparable to those initiated for squamous cell cancer of other organs. |
| Authors | E Preis, P Albers, G Jakse
(Affiliation: Urologische Klinik, Universitätsklinikum RWTH, Aachen, Germany. epreis at gmx.de)
|
| Journal | Der Urologe. Ausg. A
(Urologe A)
Vol. 45
Issue 5
Pg. 609-13
(May 2006)
ISSN: 0340-2592 Germany |
| Vernacular Title | Die systemische Therapie des Peniskarzinoms. |
| PMID | 16622642
(Publication Type: English Abstract, Journal Article, Review)
|
| Chemical References |
|
| Topics |
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chemotherapy, Adjuvant
(methods)
- Clinical Trials as Topic
- Humans
- Male
- Neoadjuvant Therapy
(methods)
- Penile Neoplasms
(drug therapy, mortality)
- Physician's Practice Patterns
- Practice Guidelines as Topic
- Terminal Care
(methods)
|
